Standards; Pharmaceutical/API Drug Impurities/Metabolites;
Deschloroempagliflozin is an impurity of Empagliflozin (E521510), a novel, potent and selective SGLT-2 inhibitor. It improves glycaemic control syndrome in diabetic rats.
Thomas, L., et al.: Diabetes. Obesity. Metabol. 14, 94 (2012); Grempler, R., et al.: Diabetes. Obesity. Metabol., 14, 83 (2012)